Medication info
Janugliptin 50 Milligrams

(Sitagliptin Phosphate)

Janugliptin 50 Milligrams (Sitagliptin Phosphate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate›62.04mg / 1 tablet
Manufacturer / importer
(Co., Ltd.) Dasan Pharmaceutical
Appearance
Bright beige, biconvex circular film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP X 3]
Approval status
Active

MFDS item code 201503179 · Approved 2015.05.27 · Insurance code 678600530

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This drug is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Because dose adjustment according to renal function is required, assessment of renal function is recommended before and periodically during treatment with this drug. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This drug may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
(Co., Ltd.) Dasan Pharmaceutical

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes and is used in conjunction with diet and exercise. Initially, it is administered as monotherapy, and if blood sugar control is insufficient, it may be combined with Metformin. Additionally, if monotherapy with Sulfonylurea, Metformin, Thiazolidinedione, or insulin is ineffective, this medication can be used in combination to treat the condition. If blood sugar control remains challenging with multiple medications, this drug can be added as well. It assists in improving blood sugar control by combining various treatment methods.

How to take

Adult dose

This drug is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Because dose adjustment according to renal function is required, assessment of renal function is recommended before and periodically during treatment with this drug. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This drug may be administered regardless of the timing of dialysis.

Precautions

This medication may cause allergic reactions; therefore, if symptoms such as skin rash, itching, or difficulty breathing occur after taking the medication, discontinue use immediately and consult a doctor. Severe pancreatitis may occur within the first 3 months of starting therapy; immediately visit a hospital if experiencing abdominal pain, vomiting, or severe discomfort in the abdomen. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication, nor should those allergic to this drug or its ingredients. Patients with decreased kidney function must adjust the dosage of this medication, requiring periodic kidney function tests. When used in conjunction with other antihyperglycemic agents, particularly insulin or Sulfonylurea, there is an increased risk of hypoglycemia, necessitating frequent monitoring of blood sugar levels and dose adjustments as needed. Serious adverse effects such as severe joint pain or bullous skin disorders can occur, so report any such symptoms to a doctor immediately. Pregnant or breastfeeding women are advised to avoid taking this medication, and safety for children and adolescents under 18 years has not been established. In case of overdose, seek immediate medical care as appropriate treatment is needed; this medication can be partially removed by dialysis. This medication generally confirms cardiovascular safety; however, greater caution is needed in elderly or those with impaired kidney function.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • upper respiratory infections
  • nasopharyngitis
  • headache
  • diarrhea
  • abdominal pain
  • nausea
Show 21 more
  • peripheral edema
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • hypoglycemia
  • dyspepsia
  • dizziness
  • elevated liver enzymes
  • vomiting
  • constipation
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent air from entering, and it is best to keep it at room temperature between 1 and 30 degrees Celsius. Proper storage maintains the efficacy of the medication and ensures safe use.

Appearance and packaging

Appearance

Bright beige, biconvex circular film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.